News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bruker Corporation to Distribute Quantinetix™ Software for Quantitative Maldi Imaging



6/20/2013 9:00:52 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BREMEN, GERMANY – June 20, 2013 – Bruker, a leading provider of MALDI imaging instruments, and ImaBiotech, a provider of innovative products and services to accelerate molecular identification and quantification, today announced a collaboration for the distribution of ImaBiotech’s Quantinetix™ software. The Quantinetix software is the first independent multi-format software for MALDI instruments that quantifies and normalizes molecules.

Mass spectrometry MALDI imaging is a technique that allows for the direct detection of drugs and metabolites in tissue, and it is increasingly being adopted as a tool for pharmaceutical drug discovery and development. But the absolute quantification of MALDI imaging data is challenging due to the complex matrix used (intact tissue) and the associated suppression of the ions that are essential to the measurement process. ImaBiotech, a leading service provider for MALDI imaging, has incorporated its special quantification methods into the Quantinetix™ dedicated software package to address these challenges.

Quantinetix™ is user-friendly software that provides quantitation of target compounds following mass spectrometry imaging experiments. It normalizes and quantifies molecules in several ways, providing images and quantitation of target compounds in over 25 organs when used for whole body distribution imaging, as well as for individual organs in targeted applications.

Dr. Sören-Oliver Deininger, Market Area Manager for MALDI Imaging at Bruker, noted, “ImaBiotech‘s Quantinetix™ software has helped transform MALDI imaging into a quantitative technique. With this collaboration, we are now able to directly provide our customers with the benefits of Quantinetix™, enabling them to achieve true quantitative results with their Bruker MALDI molecular imaging solution.”

Dr. Jonathan Stauber, CEO of ImaBiotech, added, “We are pleased to partner with Bruker. ImaBiotech’s know-how and efficiency in imaging complement Bruker’s renowned expertise in mass spectrometry. With this agreement, we are now able to offer this unparalleled technology to molecular researchers in the worldwide pharmaceutical and biomedical research industries.”

Note: Bruker MALDI imaging systems and solutions are for research use only (RUO).

ABOUT IMABIOTECH

ImaBiotech is a biotechnology company that develops quantitative tools for biomedical research and offers innovative services to accelerate molecular identification, including quantification via cutting-edge mass spectrometry and mass spectrometry imaging techniques. Its Quantinetix™ mass spectrometry imaging software is the first independent multi-format software for MALDI instruments that normalizes and quantifies molecules. For more information, visit www.imabiotech.com.

ABOUT BRUKER CORPORATION (NASDAQ: BRKR)

Bruker is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial, diagnostics and applied analysis. For more information: www.bruker.com

MEDIA CONTACT:

Vicky Lander, Bruker Daltonics

Director of Global Marketing Communications

T:+1-978-663-3660

E: vicky.lander@bdal.com

Jonathan Stauber, PhD, ImaBiotech CEO

E: contact@imabiotech.com

T:+33 (0) 320 164 090

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES